



## Contents

Meiji Holdings Co., Ltd. Annual Report 2014

### Introduction

4 T8 ● S a 8 ●

6 M ☒ G 8 ● S ...

### Our Strategy

18




## To Our Stakeholders




The Meiji Group aims to enhance corporate value continually for customers, shareholders, and other stakeholders. To this end, we will do our utmost to enrich the lifestyles of customers of all ages while growing into a global corporate group in the Food and Health fields.

## Keeping Closely in Tune with Stakeholders

Tim McGraw's success as a country music artist, songwriter, and record producer is a testament to his ability to connect with his audience. McGraw's music has resonated with millions of fans, and his success has been a major force in the country music industry. In 1991, McGraw released his debut album, "Tim McGraw," which was a commercial success. He followed up with "Not a Moment Sober" in 1993, "Before He Cheats" in 1995, and "The Time of My Life" in 1997. McGraw's music has been a major force in the country music industry, and he has won numerous awards, including the Grammy Award for Best Country Album in 2009 and the Academy of Country Music Award for Best Male Vocalist in 2011. McGraw's success is a result of his ability to connect with his audience and his commitment to his craft. McGraw's music has been a major force in the country music industry, and he has won numerous awards, including the Grammy Award for Best Country Album in 2009 and the Academy of Country Music Award for Best Male Vocalist in 2011. McGraw's success is a result of his ability to connect with his audience and his commitment to his craft.











# Yogurt

Our yogurt is the result of efforts to combine tastiness and functionality. Meiji products dominate the market because they re

N8. a a . Ja a

44.3%

Introduction

Our Strategy

# Chocolate

Our chocolate traces its history back almost hundred years. We have always been sensitive to each era's needs and taken on the challenge of developing new value. Our product lineups enjoy an overwhelming market presence.


2013 Ma 2014 a ( B a B )



24.4%

S8 : INTAGEI , SRI ( B a ) A 2013 Ma 2014 a ( B a B )













# Generic Drugs





TAKE OFF 14





T8 ● ... , l 8 ● a 8 ● 8 ● 8 ● ... 8 ● ... a a  
8 ● 8 ● ... 8 ● . T 8 ● , ... 8 ● 8 ● ... , 8 ● a ... , 8 ●  
... 8 ● ... , a ... , a ... 8 ● 8 ● ... a a ... l J a a , ... 8 ● a 8 ●  
8 ● ... 8 ● a ... a ... a ... 8 ● a ... M a ... , 8 ● a 8 ●  
a a ... , a ... 8 ● ... a ... 8 ● 8 ● a ... a a ... a ... 8 ● ...  
l ... 8 ● , 8 ● 8 ● a 8 ● 8 ● ... 8 ● 8 ● ... J a a a 8 ● a , ... 8 ●  
... 8 ● a ... a ... a ... 8 ● a ... a ; a , a ... a ; a ...  
8 ● a a ... a ... 8 ●  
T M G 8 ● 8 ● ... T a l e , E r ... , H e a ... a d R e a ... a r c e 8 ●  
8 ● 8 ● a ... , 8 ● ... a ... 8 ● 8 ● ... F ... 8 ● , ... a ... ,  
... a a ... 8 ● a ... 8 ● a ... , a ... 8 ● a a ...  
8 ● . W ... a 8 ● ... a ... 8 ● a ... 8 ● . A ... 8 ● 8 ●







8. a. 8. 8. 8. 8. a. A., a a 8. a. 8. 8. a a a. 8. 8. 8. 8. 8. 8. A 8. 8. a a a. 8. a 8. R&D, a. a R&D 8. a. a 8. 15.0 8. a 8. a a. l. a 2014, R&D 8. 8. 8. 8. a 13.0 8. 8. R&Da. a. a. 8. Ba. 8. a, Pa a a. a. 8. a. 8. 8. 7.6 8. a 2014.

F8. 8., M G 8. 8. a. 8. a. a a a. 8. a. 8. a. 8. T G 8. a 8. 8. 8. a. a a 8. a 8. , - , 8. 8. 8. a. 8. a 8. T 8. a 8a, a. a a 8. a. 8. 8. 8. F8. a. a. a. 8. 8. 8. 8. a. 8. a, a 8. a a a. 8. 61.0 8. 8. F8. a. 20.0 8. 8. Pa a a. l. F8. , 8. 8. a a 8. a. 8. 8. a: C. a, 8. 8. A a, a. U. Sa. l. a. 8. 8. a. 8. F8. a. Ta a., CP-M C8. a. a. CPG 8. a a a. a. 8., a. M B. a a Y8. 4. A. 2013. A 8. 8. D 2013. a. a. M B. a a Y8. 4. C. a, a. Sa. a 8. 8. 8. 8. a. a., M Da (S 8. C8. a. a. M Da Ta. Sa. a C8. W a 8. - a a. 8. a. a. 8. 8. 8. a. 8. 8. l. Ta a. a. C. a, 8. 8. a. a. N, a. 40 a a 8. a. M B. a a Y8. 4. Ja a, 8. a. 8. a. 8. 8. a.

a. A a.T a 8. a 8.8. 8.8.8. a  
a. 8. a 8. a 8. 8.A a a 8. 8.  
8. a 8. a 8. M XG 8. 2020V 8.

S a a a a 8. 8. 8 TAKE OFF 14. l a 2013,  
8. 9.4 8. a 8. a, 8. 47.0 8.  
a 8.8. 8. 8. 8. a a .A 8. a 2013, a  
8. a 198.3 8. 8. 7.1 8. 8. 8. a a- a,  
-8. a 8. a 0.64 .

F8. a 2014, a a a 55.0 8.8. a a , 8.0 8.  
8. 8. a a.T a 8. a a a a 8.  
a a . Ja a :a a 8. a a . Ka a . 8. a .  
a. 8. a a a . A P .F a 2014' . 8.  
8 TAKE OFF 14 8. 139.6 8. T a  
a' a a. 8. 161.7 8. 8. a . 8. 8. a . 8.

N , 8. 8. a 8. a a .  
A 8. a 8. a a a 8. 8. M . US\$290  
8. \*H8 . , 8. 55.0 8. a a . 8. a 2014. 8. 8.  
a 8. . l a . 8. a . 8. 8. a a a 8. a . a 8.  
-8. a 8. 8. TAKE OFF 14' a 8. 8. .T 8.  
8. 8. a 8. a 8.

# Food Segment

Business Results and Targets

(B 8 ● 8 ● . )

(B 8 ● 8 ● . )

⚙️ Improve profitability of whole segment by expanding and restructuring mainstay businesses

.

# Dairy Business

Net sales  
breakdown by  
Food segment

Fiscal 2013

Net Sales **¥638.7** billion U 4.3% a.g. a ↑

- In yogurt, sales of probiotic yogurts grew significantly because of marketing campaigns to increase brand recognition. Consequently, the product mix improved. Although sales of “Meiji Bulgaria Yogurt” declined year on year, “Meiji Bulgaria Yogurt Drink” sold briskly thanks to customer endorsement of new packaging.
- While drinking milk sales were lower than those in the previous fiscal year, sales of “Meiji Oishii Gyunyu” were higher due to successful marketing highlighting its distinctive value.

Operating Income **¥25.3** billion U 37.3% a.g. a ↑

- In processed food products, sales of cheese rose year on year as “Meiji Hokkaido Tokachi Camembert Cheese” performed favorably. Despite market sluggishness stemming from extreme summer heat, sales of margarine for commercial use were maintained year on year.
- The dairy business achieved higher revenues and earnings due to improved efficiency, reduced costs, and revised product strategies. These factors more than compensated for increased raw material costs, including imported dairy ingredients, and advertising expenses.

## Initiatives in Fiscal 2013

### Established Overwhelming Superiority in Yogurt Market

- Total sales of yogurt products in Japan reached 340 billion yen, a 30% increase from 260 billion yen in the previous fiscal year. This growth was driven by the success of “Meiji Bulgaria Yogurt Drink” and “Meiji Oishii Gyunyu”.

### Efforts to Offset Higher Raw Material Costs

- We implemented cost-cutting measures in various areas, including logistics and production efficiency, to offset the impact of higher raw material costs.

## Goals for the Final Year of TAKE OFF 14

- We are increasing the competitive superiority of the yogurt business. For probiotic yogurts, we are continuing marketing campaigns to increase brand recognition while raising production capacity.
- The Meiji Group is continuing structural reform. For lower margin products, we are reassessing and adjusting pricing, net volumes, and packaging. To reduce costs, we are improving the efficiency of production and logistics.
- Scheduled to begin operating in fiscal 2014, a new plant in Aichi Prefecture will become our core plant in the Tokai area for the production of fresh dairy products. We will improve logistics efficiency by integrating and relocating some of the area's chilled and room-temperature warehouses to the new plant, which will also serve as a logistics base.

# Confectionery Business

## Increased Profitability and Product Appeal

- F&B, C&S, and M&M's, a leading confectionery brand, has achieved a significant increase in profitability and product appeal.
- This is primarily due to the company's focus on innovation and quality, which has resulted in a strong market presence and a loyal customer base.



# Other Businesses

## Products We Sell Overseas



## Goals for the Final Year of TAKE OFF 14







# Ethical Pharmaceuticals Business

## “Specialty and Generic”

● M... a... a... (MR) 8... 8... a... a...  
8... a... '... a... a... a... a...  
...T... a... a... 8... a... #  
8... 8... 8... a... 2013, ... a... a...  
a... a... 8... 8... P a... a...

● W... a... 8... 8... 8... a...  
a... a... a...

## Realize Global Business Development and Low-Cost Operations

● Overseas sales of the company's main products, including the anti-infective drugs "MEIACT" and "ORAPENEM" and the anti-depressant drug "REFLEX" are increasing.

● We are expanding overseas businesses in emerging countries in Asia and other regions.

## Effective R&D Investment and Acceleration of Drug Development

● We are accelerating R&D investment in the development of new drugs, including the anti-infective drugs "MEIACT" and "ORAPENEM" and the anti-depressant drug "REFLEX".

● We are accelerating the development of the anti-infective drug "MEIACT" and the anti-depressant drug "REFLEX" (April 2013).

● We are accelerating the development of the anti-infective drug "MEI1111" (April 2013).

● We are accelerating the development of the anti-infective drug "ME1100" (April 2013).

● We are accelerating the development of the anti-infective drug "LASERPHYRIN 100" (April 2013).

● We are accelerating the development of the anti-infective drug "O 9" (April 2013).

## Goals for the Final Year of TAKE OFF 14

- The NHI drug price revisions in fiscal 2014 surpassed our expectations when preparing TAKE OFF 14. Therefore, we are counteracting the effects of these revisions as a priority task.
- As a "Specialty and Generic Pharmaceuticals Company," we are promoting the antibacterial drugs "MEIACT" and "ORAPENEM" and the antidepressant drug "REFLEX" and growing sales of generic drugs.

- We are using our global production system based on the selection of optimal sites to increase production capacity. Also, we are improving our profitability through cost reduction in procurement and production divisions.
- We are expanding overseas businesses in emerging countries in Asia and other regions.

● We are accelerating the development of the anti-infective drug "MEIACT" and the anti-depressant drug "REFLEX" (April 2013).

● We are accelerating the development of the anti-infective drug "ME1100" (April 2013).

# Agricultural Chemicals and Veterinary Drugs Business

- Sales of agricultural chemicals rose year on year because sales of



# Corporate Governance

## Fundamental Policy

R... M G8'S 8... , M G8...  
... a a a a 8... 8... , 8... , a 8...  
a... 8... , 8... , a a 8... a 8... a a  
8... a a... 8... 8... 8... 8... 8... ,  
... 8... a... a... 8... 8... 8... a 8... 8... 8...  
a 8... 8... 8... a , M G8... a 8... 8...  
8... 8... a 8... 8... .

## Reasons for Appointment of Outside Audit & Supervisory Board Members

---

Kenichi Yamaguchi

TC8 ● a a a B ● . M. Ya a a a B ● . a . & B ●  
8a ● a a a a . . . . a . . . . -  
a a a a B ● .

---

Hajime Watanabe

TC8 ● a a a B ● . M. Wa a a a B ● . a . & B ●  
8a ● a a a a . . . . a . a .

---

---


  

---

# Board of Directors and Audit & Supervisory Board

As of March 27, 2014



## Members of the Board of Directors



A . 2009 (A8 ● 1966 (8) ● MM8 ● 135) -5 ( (MT ● )) JTJETBT6 0 0 6 21.0236 598.0613 T /T 2 1 J ) 1 ( (U ) -501 (2009 (OT 48 ( ) 219 (G) -5 ( ) 219 (M) --35 ( ) 45 ● P) 8 ( a ) 11 | (2766 ( A 4 ( ) 8 ( a A 8 ● T ● )) JTJETBT6 0 0 6 21.  
 A . 1994 G . a Ma a ● , Ma ● . Pa ● .  
 D a ● . , M ● Da ● .  
 J . . 1995 D ● 8 ● M ● Da ● .  
 J . . 1995 G . a Ma a ● , P ● 8 ● D a ● . ,  
 M ● Da ● .  
 J . . 1999 S . 8 ● Ma a ● . D ● 8 ● M ● Da ● .  
 J . . 2001 E ● V ● P ● . a R ● . a  
 D ● 8 ● M ● Da ● .  
 A . 2003 P ● . a R ● . a D ● 8 ●  
 M ● Da ● .  
 A . 2009 E ● V ● P ● . a R ● . a  
 D ● 8 ● M ● H8 ● .  
 A . 2011 R ● . a D ● 8 ● M ● H8 ● .  
 A . 2011 P ● . a R ● . a D ● 8 ● M ●  
 J . . 2012 P ● . a R ● . a D ● 8 ●  
 M ● H8 ● .  
 J . . 2012 M ● 8 ● 8 ● , M ●  
 J . . 2012 M ● 8 ● 8 ● , M ● S a Pa a  
 ( ● )  
 J . . 2014 C a a a R ● . a D ● 8 ●  
 M ● H8 ● . ( ● )

### Significant concurrent positions

D ● 8 ● M ● S a Pa a  
 C a a , Ja a Da A 8 ● 8 ● (JM )  
 C a a , T Ja a C8 ● a a  
 Pa a R ● . A 8 ● 8 ●



A . 1981 J8 ● M ● S a  
 J . . 2012 G . a Ma a ● , P ● R a 8 ● D a ● . ,  
 M ●  
 J . . 2013 E ● O ● , M ●  
 J . . 2014 M ● 8 ● B8 ● a E ● O






A . 1976 J8 ● M ☒Da  
 A . 2007 G . a Ma a . , N . 8 . C8 ● 8 ● a .  
 Ma . . D . 8 ● M ☒Da  
 J . . 2007 D . 8 ● M ☒Da  
 J . . 2009 E . . O . , M ☒Da  
 J . . 2010 D . 8 ● Ma a . . E . . O . ,  
 M ☒Da  
 A . 2011 M . 8 ● . 8 a . a . S . 8 ● Ma a . .  
 E . . O . , M ☒  
 J . . 2012 P . . a . R . . a . D . 8 ●  
 M ☒( . . )  
 J . . 2012 M . 8 ● B8 a . , M ☒H8 ● . .  
 ( . . )

Signi cant concurrent positions

P . . a . R . . a . D . 8 ● M ☒




A . & S 8 ●  
 B8 a ● M  
**Hideaki  
 Sato**

A . 1976 J8 ● M ☒Da  
 J . . 2009 E . . O . , M ☒Da  
 A . 2011 E . . O . , M ☒  
 J . . 2013 A . & S 8 ● B8 a ● M ☒ ,  
 M ☒H8 ● . . ( . . )



A . & S 8 ●  
 B8 a ● M  
**Hiroshi  
 Tago**



A . & S 8 ●  
 B8 a ● M  
 (O . . )  
**Kenichi  
 Yamaguchi**



A . & S 8 ●  
 B8 a ● M  
 (O . . )  
**Hajime  
 Watanabe**

l a 2013, Ma 31, 2014, Ja a ' 8.8. 8.8.  
8.8. A a a 8.8. a 8.8.  
8.8., 8.8. a, 8.8., a a.



T8 ● a a . . . 8 ● 8 ● 8 ● a . . a a . .  
a 8 ● . . 8 ● 779,461 8 ● 8 ● 6,052 8 ● 8 ●  
8 ● a a - . . . T . . . a . . . . a  
8 ● 13,705 8 ● . . 8 ● a . a 8 ● a a . . 38,373

(3) W

T M  G 8 ● ' a . . a . 8 ● 8 ● . . a  
a





	M 8 ● 8 ●		T 8 ● a 8 ● U.S. 8 ●
	2014	2013	2014
(NB ● 21)	1,174,007	1,126,520	\$11,155,033
	754,013	743,835	7,32,212
G 8 ● 8 ●	34,02	382,684	3,22,21
(NB ● 20,21)	357,55	356,825	3,77,211
O a ● ● 8 ●	34	25,859	354,10
( )			
l a ● ● ● ● ● 8 ●	97	919	,54
l	(1,200)	(1,549)	(12,517)
E ● ● 8 ● 8 ● a	297	310	2,77
R ● ● 8 ● 8 ● a a	2,321	2,258	22,550
R ● 8 ● 8 ● a a	(1,052)	(1,894)	(17,00)
O	2,13	3,227	20,754
E a 8 ● a a (NB ● 22)	1,500	2,540	15,440
E a 8 ● a 8 ● (NB ● 22,23)	(,1)	(6,457)	a 30 695.1527

00 325.



	Millions of U.S. Dollars		Total U.S. Dollars
	2014	2013	2014
(Note 24)	1,012	16,847	\$1,012,533
Net sales	3,000	7,459	2,733
Depreciation and amortization	75	1,486	7,301
Financial income	3,433	1,978	3,320
Equity-based compensation	175	148	1,707
Total	7,332	11,072	77,177
	2,332	27,919	\$2,332,088
( )			
Cost of sales	2,715	27,529	\$25,577
Cost of services	21	390	2,10

Sales and services revenue





1.

T a 8 ● a . . . 8 ● 8 ● a . . . a a a . . . 8 ● M ☒  
H8 ● . . . C8 ● L . . . ( . . . C8 ● a ) a . . . 8 ● 8 ● a . . . -  
a . . . a . . . a . . . 8 ● . . . 8 ● 8 ● a . . . a a a -  
. . . . . Ja a . . . . . Ka 8 ● 8 ● F a . . B a a  
. . . . . F a a l . . . . . a . . E a . . La . T  
a . . . 8 ● 8 ● 8 ● . . a a . . . a 8 ● . . . .  
a . . . a . . . Ja a , . . . a . . . . . a .  
. . a . . . a . . a 8 ● a . . . 8 ● . . . . . 8 ● . . a -  
8 ● F a a R 8 ● . . Sa . a . . T . . 8 ● 8 ● a . . . a a  
a . . . a . . 8 ● . . . . 8 ● . . . . . a a 8 ● 8 ●  
8 ● 8 ● a 8 ● 8 ● a

l. F88... a. - 8 a  
8 a 8 ( ... aa 8 8  
8 , a a ... 8 a a ( ...  
a a ... ), a , a a 88 a  
8 8 a a 8 ). F8 P a a a  
a a 8 C8 a , ... aa 8  
8 a 8  
D a 88 ( ... a a ) a  
88 A 1,1998, a a a. - 8

O a 88 a  
T a. - 8 a 8 a 8  
T a ... 8 a a a 88:  
B ... a ... 2-60 a  
Ma ... , ... a ... 2-18 a  
T88 ... a ... 2-20 a

) ( )  
A 8 a 88 a ... a a a  
a. - 8 A 8 a 88 a - 8 a  
a a ... a. - 8 a 8 a

)  
 Ca a . a . a . . . 8 ● 8 ● a . . a . . 8 ● a  
 8 ● a . 8 ● 8 ● 8 ● a . 8 ● a . . , a . . 8 ● a a a . 8 ●  
 . . a a 8 ● . a . a . 8 ● . . . . . 8 ● . a  
 a . 8 ● . 8 ● 8 ● , . a . . 8 ● 8 ● a -  
 8 ● . a .

)  
 (1) Method of hedge accounting  
 T . . a . . a 8 ● . . . . 8 ● a . . . .  
 . . a . . a . 8 ● 8 ● . . . . a a 8 ● 8 ● . 8 ● a  
 . . a . . a a . . .  
 F8 ● 8 ● a . 8 ● . . . a . . 8 ● a . . , . . a 8 ● 8 ●  
 8 ● a . . . . . a . . a a . . F8 ●  
 a . a , . 8 ● . 8 ● a . . . . . a  
 a a . . .

(2) Hedge instruments and hedged items

H . . . . . :	H . . . . . :
F8 ● a . 8 ● . . a . 8 ● a . a . 8 ●	T a . a a . a . a . . 8 ● a . . 8 ● . . a . 8 ● a . . a a 8 ● . . 8 ● a . . 8 ● . .
l . . a . a 8 ● a	l . . 8 ● 8 a . a a

5.

( )

F. a a a a 8. 8.8. 8.8.a

(1) Content of lease assets

P8. , a a.









A 8 Ma 31,2014, a . . a a . a a 8 8 - 8 a a a a 8 8 (8 a 8 ):

	M 8 8 .		T 8 a 8 . U.S. 8 .
	2014	2013	2014
M8 a 8 a 8 8 a	07		\$ 47
M8 a 8 a 8 a	5		375
M8 a a 8 8 a	20,11		1 5,45
M8 a 8 a 8 a	10, 77		103,743
M8 a a	2,070		20,11
T8	37, 30		\$33, 2

l . 8 a 8 Ma 31,2014 a . 2013, a a 8 8 :

	M 8 8 .		T 8 a 8 . U.S. 8 .
	2014	2013	2014
G88 a . 8	0,215	81,339	\$ 77 ,3 3
WB . 8	2,505	2,229	2,344
Ra a a a .	3, 41	37,624	37,3 2
T8	121, 1	121,194	\$1,12,100

10.

A a 8 . . a 8 a 8 a a 8 Ma 31,2014 a . 2013, a 8 8 :

	M 8 8 .		T 8 a 8 . U.S. 8 .
	2014	2013	2014
B . . a .	2, 72	2,250	\$ 2,5 2
Ma . . , . . a .	1, 0	776	1, 41
La .	4,05	2,988	3, 3
O	15,7	16,750	153,507
T8	27, 0	22,765	\$23 , 7

A a 8 . . a a 8 Ma 31,2014 a . 2013, a 8 8 :

--	--	--	--



**12.**

Outline of the retirement benefit plans adopted by the Company (As of March 31, 2014)

T 8 ● a 8 ● 8 ● /

4)

	M 8.8.8.	T 8.8.8. U.S. 8.
	2014	2014
S 8.	4,27	\$ 41,4
l 8.	2,002	1,452
E . . . 8. a a	(2,200)	(22,231)
A 8. a 8. 8. a a. a. / 8.	0	7; 5
A 8. a 8. 8. 8. 8.	4	21
O	701	,20
R . . . 8. a . 8. . . . a	12,4	\$12, 7
(NB) l . . . 8. a a . . . . 8. ( . . . 8. a . . . 8. . . . a a . 8. 8. 8. . . a a . ) a . . . . 8. . . . 8. . . . 8. . . . 8. 8. 8. 8. 8. . . . 8. . . .		

5)

T a . 8 . 8 . . . . 8 . . . . a . . . . 8 . . . . 8 . . . . 8 69263.8646 5288T /T 55 1 T [(12 )-11 (3 9 0 0 9 154.5611 T (I) T BT 424 8 . )]

( 31, 2013)

La	8 ● 8 ●	M 8 ● 8 ●
R	8 ● a 8 ●	2013
Fa a	8 ● 8 ● a a	(121,019)
U	8 ● a 8 ●	95,492
U	8 ● 8 ● a 8 ● a a 8 ●	(25,526)
U	8 ● a a a 8 ●	1,438
U	8 ● 8 ● 8 ●	35,040
N	8 ● a 8 ●	169
P a	8 ● 8 ●	11,122
A	8 ●	33,460
		(22,338)

T 8 ● 8 ● 8 ● 8 ● 8 ● 8 ● a Ma 31, 2013, a a 8 ● 8 ●:

S	8 ●	M 8 ● 8 ●
I	8 ●	2013
E	8 ● a a	3,984
A 8 ● a 8 ● 8 ●	8 ● a 8 ● a a 8 ●	2,325
A 8 ● a 8 ● 8 ● a a 8 ●		(1,887)
A 8 ● a 8 ● 8 ● 8 ● 8 ●		711
C 8 ● 8 ● 8 ● 8 ● 8 ●		6,608
A 8 ● a 8 ● a 8 ● a 8 ● a		55
O (NB ●)		197
N	8 ● 8 ●	31
		1,041
		13,068

(NB ●) T 8 ● 8 ● 8 ● 8 ● 8 ● 8 ● a a S a E R A 8 ● M a A

A 8 ● a 8 ● 8 ● a 8 ● a 8 ● a Ma 31, 2013, a 8 ● a 8 ● 8 ●:

P 8 ● 8 ● 8 ● 8 ●	8 ● a 8 ●	P a	a - 8 ●
D 8 ● a		P a	1.5% 8 ● 1.7%
E a 8 ● 8 ● a a			2.5%
A 8 ● a 8 ● 8 ● 8 ● a a a / 8 ●			7 8 ● 5 a
A 8 ● a 8 ● 8 ● 8 ● a 8 ●			
8 ● a 8 ●		P a	15 a
A 8 ● a 8 ● 8 ● 8 ● 8 ●		P a	4 a

13.

A 8 ● Ma 31, 2014 a 2013, a a 8 ● 8 ● 8 ● a a a a a 8 ● 8 ●:

O (. a a)	M 8 ● 8 ●		T 8 ● a 8 ●
	201 <sup>4</sup>	2013	U.S. 8 ●
	3, 13	5,484	201 <sup>4</sup>
			\$3,002

14.







22.

T a 8 . . . 8 . a 8 . a . a . a . 8 . . . . a . a . . . Ma 31, 2014 a . 2013, a a 8 . . . :

	M 8 . . . .		T 8 . a . 8 . U.S. 8 .
	2014	2013	2014
E a 8 . a . a . :			
Ga. 8 . a 8 . . a	55	2,154	\$ ,372
Ga. 8 . a 8 . . .	577	97	5,320
Ga. 8 . a 8 . a 8 . . a a . a . a	25		2,407
O	12	288	1,25
<b>T 8 .</b>	<b>1,501</b>	<b>2,540</b>	<b>15,770</b>
E a 8 . a 8 . . :			
L 8 . . . 8 . . 8 . . a	2,720	2,303	2 ,433
L 8 . . a 8 . . a	223	841	2,172
I a . . 8 .	3, 12	76	35,101
L 8 . . a a 8 . . 8 .	25	864	2401
L 8 . . a a 8 . . 8 . . . a a 8 . . a a . a . a		1,038	
O	401	1,335	3, 71
<b>T 8 .</b>	<b>, 1</b>	<b>6,457</b>	<b>\$ 7, 27</b>

(NB) I a . . . 8 . . a . 8 . a 8 . . . . # a . . . 8 . . 4 . . 8 . . 8 . . ( . . ) # . . . 8 . . 8 . . 8 . . a . a 8 . . . . 8 . . a a 8 . . 8 . . 8 . . a a 8 . . . . 8 . . . . a . a . 8 . . a 8 . . . . # . . . . 10% 8 . . 8 . . a 8 . . 8 . . 8 . . 8 . . ( . . ) # 8 . . 8 . . a . . . a . . a . . 8 . . 8 . . 8 . . 8 . . a . a . a . . 8 . . 8 . . 8 . . a . a 8 . . . . 8 . . a . . . . A a . . . 8 . . 8 . . a . . 8 . . 8 . . 8 . . 8 . . 8 . . 8 . . a . a . . . 8 . . 4 . . 8 . . 8 . . ( . . ) # a . . . a . a . a . a . 8 . . a 8 . . . . # 8 . . 97 . . 8 . . a . . 8 . . 4 8 . . 288 . . 8 . .

23.

I a . . 8 . . 8 . . a . a . . . Ma 31, 2014, a a 8 . . . :

A a 8 .	T	L 8 . 8 .
B . . a	Ma . . , . . . . a . a . . .	M 8 - 8 , Ka a - , H 8 . a 8 .
B . . a	Ma . . , . . . . a . a . . .	S a a a - , Na a a P
I a	B . . . . .	N . a a - , N . a a P
I a	Ma . . , . . . . a . a . . .	F 8 . - , F 8 . P
B . . a	Ma . . , . . . . a . . . . .	A 8 . - , A P
A . . . 8 . . a	La . . . . .	Ka a a - , C a P

T a . . 8 . . . . G 8 . . a . . . a . 8 . . . 8 . . . . R . a a a . . . a . a . 8 . . . . . a a . . . F 8 . . a . a . . . Ma 31, 2014, . . 8 . . a . . . 8 . . a . . . a . . 8 . . 8 . . 8 . . a . . . a . . 8 . . 8 . . 8 . . a . . . a . . . . , a . . . 8 . . a . . . 8 . . a . . . a . . 8 . . C 8 . . a . . , a . . . a . . 8 . . a . a . . . . 8 . . 8 . . 8 . . a . a 8 . . , a . . 8 . . . . 8 . . . . 8 . . . . a 8 . . a 8 . . a . a . . 8 . . 8 . . 3,612 . . (\$35,101 . . 8 . . a . .).

l a 8 8 a a Ma 31,2013,a a 8 8:

A a 8

T

l 8 8

l a

B a a

l a a- ,C aP , .

T a 8 . . . G 8 a . . . a . 8 . . . 8 . . . R . a a . . . a . 8 . . . . a a .  
F 8 .



Ma a . 8 ● a a a 8 ● . a a . . . Ma 31,2013

1)

(1) Currency-related transactions

	M 8 ● 8 ● .			
	2013			
	C8 ● a a 8 ● , .	P8 ● 8 ● a 8 ● a	Fa a	R a a 8 ● . a. (8 ●)
Ta a 8 ● 8 ● a a				
a a 8 ● :				
F8 ● a . 8 ● . a . 8 ● a				
B				
U.S. 8 ●	539		(24)	(24)
S				
U.S. 8 ●	47		(5)	(5)
E 8 ●	272		(29)	(29)
C . a 8 ● a				
B				
U.S. 8 ●	3,555	3,216	(142)	(142)
O 8 ● 8 ● a				
S				
P 8 ● 8 ●				
U.S. 8 ●	362		6	

2)

(1) Currency-related transactions

---





---

---

---

---

---


---

---

---



# Independent Auditor's Report



# Major Group Companies

Head Office

Research Laboratories

0



# History

## 1900s–1940s

1906	T 8 ● M S a C8, ( a M S a), 8 ● 8 ● M S a Ka a, L ( a M S S a), a M Da C8 ● 8 ● ( a M Da ), a
1916	T8 ● 8 ● 8 ● C8, ( a T8 ● C8 ● 8 ● + 8 ● M S a), a
1917	T8 ● 8 ● 8 ● Ta 8 S a, a a 8 ● M S a. K 8 ● 8 ● M C8, ( a K 8 ● 8 ● C8 ● M ), 8 ● M Da a
1920	M S a a M S 8 ● (a M S 8 ●)
1924	T8 ● 8 ● 8 ● a a 8 ● M S a Ka a, L
1926	M S a a M M C 8 ● + M S a a a 8 ● 8 ●
1928	M S a a M M +
1940	K 8 ● 8 ● M a a 8 ● M Da C8 ● 8 ● 8 ●
1946	T a a a a 8 ● 8 ● 8 ● 8 ●

## 1950s–1960s

1950	T a a a STREPTOMYCIN+ 8 ●
1951	M Da a S 8 ● C M l a F 8 ● a+
1953	M Da a M F C a +
1958	Ja a ' 8 ● - a a a a , KANAMYCIN+ 8 ●
1961	M S a a Ma C 8 ● +
1968	M S a a Ja a ' a 8 ● a , Ka + M Da a a 8 ● 8 ● M Ba R G ta M l a Ka O a J +

## 1970s

1971	M Da a M Pa Y 8 ● +
1972	M S 8 ● M S a' a a , a a 8 ● 8 ● M Da M S a M S 8 ●
1973	M Da a M B a a Y 8 ● +
1974	M S a (S a 8 ●) P . L . a T ● . P.T.M l . 8 ● a P a a a l a
1975	M S a a 8 ● a K 8 ● 8 ● a + T a a a 8 ● ORYZEMATE+ 8 ●
1976	M Da a 8 ● 8 ● P a & P a +

## 1980s

1980	M S a a SAVAS+ 8 ● 8 ● 8 ●
1983	M S a a OTC ISODINE UGAIGUSURI+
1986	M Da a a 8 ● a YH-80+
1988	M S a a Ka G +
1989	M Da a CP-M C8, , T a a T a a MEILAX+ 8 ●

## 1990s

1990	M Da a A a+ 8 ● a
	M Da a a 8 ● a a , M C8 ● 100+
1992	M Da a M H 8 ● a 8 ● C +
1994	M Da a M E S C U a Va a+ T a a a MEIACT+ 8 ●
1995	M Da a 8 ● 8 ● a VAAM+ M Da a a 8 ● a M M Ba a +
1997	M S a a X G +
1999	T a a a DEPROMEL+ 8 ●

## 2000s

2000	M Da a M P 8 ● 8 ● LG21+
2002	M Da a 8 ● 8 ● M O G + a 8 ● M S a a A 8 ● 8 ● +
2007	M Da a a 8 ● a M H 8 ● Ra Ra C +
2008	M Da a M F C a A a +
2009	M S a a M Da a a 8 ● 8 ● 8 ● a M H 8 ● C8, , a a a a T a a a ORAPENEM+ 8 ● T a a a REFLEX+ 8 ●

## 2010s

2010	P a M G 8 ● 2020V 8 ● a a 8 ● - a a M Da a M Y 8 ● R-1+
2011	l A , M H 8 ● 8 ● a M S a a M Da ; M C8, , a 8 ● 8 ● a , a M S a P a a C8, , a a a a 8 ● a , 8 ● a 8 ●

